Loading…
← CockpitCompetitor Analysis › 301080.SZ Acrobiosystems Co., Ltd. Class AOpen in the cockpit ↗

Acrobiosystems Co., Ltd. Class A301080.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Chinese life-science reagent supplier making recombinant proteins and antibodies used in biopharma R&D, diagnostics and vaccine development.

≈ A Chinese Bio-Techne/R&D SystemsMomentum leader 94
Mkt cap
$2.31B
US dollars, full cap
Free float
63%
of shares outstanding
$/day
$220M
20-day average traded
Fwd P/E
55.2×
forward earnings
ROIC−WACC
-1.2 pp
WACC 11.6%
Hurdle
+14 pp
Req g minus delivered
Next earnings
159 days
26 Apr 2027
Close · CNYCN¥74.21
1D-0.3%
1W-20.7%
1M-23.9%
3M-15.9%
6M+65.3%
YTD+37.4%
1Y+23.0%
ATR %13.0%
52w lowhigh47.4% off high

What Acrobiosystems does

Chinese life-science reagent supplier making recombinant proteins and antibodies used in biopharma R&D, diagnostics and vaccine development.

Sells off-the-shelf research proteins and antibodies, ordered by lab scientists in small lots, and higher-grade versions made to manufacturing standards for drugmakers, so revenue builds on a wide catalog and repeat purchasing. Customers range from large drug developers to academic labs, and a sizeable share of sales is exported.

In one line: A Chinese Bio-Techne/R&D Systems.

Products and services

  • Recombinant proteins
  • Research antibodies
  • Assay/reagent kits

Customers

  • Biopharma and biotech R&D labs
  • Diagnostic/vaccine developers

Where it sits in the supply chain

  • Health Care
  • Life-science tools
  • Recombinant protein/antibody reagents

What could go right

  • Global biopharma R&D spending growth

What could go wrong

  • Biotech-funding cycle sensitivity
  • Competition from global life-science tool vendors

Moat: narrow (scale, process know-how, installed base). Broad, validated catalog of research-grade proteins used across many biopharma R&D pipelines.

Headquarters: Beijing, China · Employees: 926

Named competitors

Acrobiosystems at a glance

Size Acrobiosystems (301080.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $2.31B, the 1039th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥74.21 on 18 Nov 2026.

Performance Over six months the shares gained 65.3%, against -11.5% for the median peer and -20.0% for the China market (cap-weighted) — highest of 21 in its peer set.

Growth Revenue grew 29.1% over the last twelve months (peer median +4.2%); the operating margin is 17.2% (peer median 9.1%).

Valuation It trades at 55.2× forward earnings against a peer median of 21.6× (3rd most expensive of 15).

Price implies For today's price to make sense, revenue must grow about 41% a year for seven years (Req g). Recent delivered growth is +28%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 1.2 points below its cost of capital (11.6% WACC).

Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).

Relative performance

10020030021 May 202621 Aug 202618 Nov 2026301080.SZ 171Peer median 89
Six months, rebased to 100: Acrobiosystems against the median of its 20 peers (local-currency closes).

Acrobiosystems financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.03BCN¥837MCN¥644MCN¥543MCN¥474M
Revenue growth—+30%+19%+15%—
Gross profitCN¥945MCN¥710MCN¥538MCN¥456MCN¥414M
EBITDAn/aCN¥204MCN¥131MCN¥137MCN¥160M
Net incomeCN¥195MCN¥166MCN¥124MCN¥154MCN¥204M
Free cash flowCN¥206MCN¥255M-CN¥82.4M-CN¥12.2M-CN¥61.0M
Capital expenditureCN¥236MCN¥205MCN¥167MCN¥129MCN¥284M
Total debtCN¥129MCN¥122MCN¥143MCN¥102MCN¥71.5M

Quarterly statements and history in the cockpit →

Acrobiosystems competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%RGCPRGO000250NAMS001360385821623696PBHAPLLTD600867600267214450IDYAH02688428600285301080.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Acrobiosystems is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%25×50×75×PRGO001321623696PBHAPLLTD600867600267301301214450688428301080.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Acrobiosystems is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%PRGO0013603858PBH214450688428301080.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Acrobiosystems is the large dot.

Acrobiosystems competitors and peer comparison

Head to head with its named competitors (301080.SZ vs 301047.SZ vs TECH vs TMO)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Acrobiosystems 301080.SZ$2.31B+65%+29%17%55.2×41.3%
Sino Biological 301047.SZ$1.60B+27%+20%17%51.6×31.1%
Bio-Techne TECH$11.4B+56%+1%21%34.4×31.6%
Thermo Fisher Scientific TMO$257B+53%+8%19%25.7×21.3%

How Acrobiosystems compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Acrobiosystems against its 20 peers (data as of 18 Nov 2026)
Measure301080.SZPeer medianRank in peer set
1-month return-23.9%-4.4%4th lowest of 21
6-month return+65.3%-11.5%highest of 21
Distance from 52-week high-47.4%-30.8%6th lowest of 21
Revenue growth (TTM)+29.1%+4.2%3rd highest of 20
Operating margin17.2%9.1%6th highest of 19
Forward P/E55.2×21.6×3rd most expensive of 15
Growth the price implies (Req g, 7 yrs)41.3%2.8%2nd most demanding of 15
Growth delivered (Del g)+27.7%+6.5%3rd highest of 15
Hurdle (Req g minus delivered)+13.6 pp-0.5 pp4th most demanding of 15
ROIC minus cost of capital-1.2 pp-1.3 pp8th highest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Acrobiosystems 301080.SZChina$2.31B+65%+29%17%55.2×41.3%+27.7%
Regencell Bioscience RGCUnited States$2.33B-83%n/an/an/an/an/a
Perrigo PRGOUnited States$2.35B+52%-4%5%6.7×14.1%+0.8%
Sam Chun Dang Pharm 000250.KSSouth Korea$2.36B-66%+23%7%n/an/an/a
NewAmsterdam Pharma NAMSUnited States$2.37B-45%-26%-900%n/an/an/a
HUTCHMED (China) 0013.HKHong Kong$2.38B+14%-9%-6%35.9×47.0%+19.3%
Shandong Buchang Pharmaceuticals 603858.SSChina$2.25B-7%+4%10%n/a-2.5%-5.8%
Keymed Biosciences 2162.HKHong Kong$2.39B+7%0%-73%18.2×n/an/a
InSilico Medicine Cayman TopCo 3696.HKHong Kong$2.40B-33%+153%-7%85.2×37.9%+22.9%
Prestige Consumer Healthcare PBHUnited States$2.40B+7%+5%25%10.6×2.3%+2.9%
Alembic Pharmaceuticals APLLTD.NSIndia$2.20B+39%+20%12%25.0×26.7%+6.5%
Tonghua Dongbao Pharmaceutical 600867.SSChina$2.19B-12%+18%n/a25.4×0.9%+0.3%
Zhejiang Hisun Pharmaceutical 600267.SSChina$2.19B+14%-7%15%15.0×-9.7%-1.5%
Almirall ALM.MCSpain$2.46B-13%+24%8%27.1×6.1%+6.5%
Yili Chuanning Biotechnology 301301.SZChina$2.49B-24%-14%16%27.6×3.4%+4.8%
PharmaResearch 214450.KSSouth Korea$2.10B-24%+29%37%15.4×-11.0%+37.6%
IDEAYA Biosciences IDYAUnited States$2.56B-11%-83%-1,267%n/an/an/a
Haw Par H02.SISingapore$2.08B-25%-13%30%11.9×3.2%+15.7%
InnoCare Pharma 688428.SSChina$2.07B-7%+135%35%85.7×-10.9%+344.2%
Kangmei Pharmaceutical 600518.SSChina$2.61B-21%-6%-7%n/an/an/a
Henan Lingrui Pharmaceutial 600285.SSChina$2.04B+9%+5%22%15.9×-4.7%+10.6%

Questions

Who are Acrobiosystems's main competitors?
Named competitors: Sino Biological (301047.SZ), Bio-Techne (TECH), Thermo Fisher Scientific (TMO). The cockpit's measured peer set (industry) also includes Regencell Bioscience (RGC), Perrigo (PRGO), Sam Chun Dang Pharm (000250.KS), NewAmsterdam Pharma (NAMS), HUTCHMED (China) (0013.HK), Shandong Buchang Pharmaceuticals (603858.SS).
Is Acrobiosystems expensive compared with its peers?
On forward p/e it trades at 55.2× against a peer median of 21.6×, 3rd most expensive of 15 in its peer set. For today's price to make sense, revenue must grow about 41% a year for seven years (Req g). Recent delivered growth is +28%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Acrobiosystems stock performed?
Over six months to 18 Nov 2026 the shares returned +65.3% against -11.5% for the median peer; over one year +23.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.